Icon Bioscience, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2004-01-01

Employees: 51

Market Cap: -

Website: http://www.iconbioscience.com

Clinical Trials

Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery

Phase 3

Completed

Conditions: Cataract

Interventions: Drug: Dexamethasone
Drug: Prednisolone

First Posted Date: 2015-09-11

Last Posted Date: 2018-08-21

Lead Sponsor: ICON Bioscience Inc

Target Recruit Count: 194

Registration Number: NCT02547623

Locations: 🇺🇸
Inland Eye Specialists, Hemet, California, United States
🇺🇸
Kislinger MD inc, Glendora, California, United States
🇺🇸
Harvard Eye Associated, Laguna Hills, California, United States

and more 7 locations

The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

Phase 3

Completed

Conditions: Inflammation
Cataracts

Interventions: Drug: IBI-10090
Drug: Placebo

First Posted Date: 2013-12-10

Last Posted Date: 2018-04-23

Lead Sponsor: ICON Bioscience Inc

Target Recruit Count: 394

Registration Number: NCT02006888

Locations: 🇺🇸
Hull Eye Center, Lancaster, California, United States

Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

Phase 2

Completed

Conditions: Inflammation Associated With Cataract Surgery

Interventions: Drug: IBI-10090

First Posted Date: 2012-05-28

Last Posted Date: 2014-09-22

Lead Sponsor: ICON Bioscience Inc

Target Recruit Count: 172

Registration Number: NCT01606735

Locations: 🇺🇸
Inland Eye Specialists, Hemet, California, United States
🇺🇸
California Eye Professionals, Temecula, California, United States

Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

Phase 2

Terminated

Conditions: Ocular Inflammation

Interventions: Drug: IBI-10090

First Posted Date: 2010-10-04

Last Posted Date: 2013-09-18

Lead Sponsor: ICON Bioscience Inc

Target Recruit Count: 42

Registration Number: NCT01214174

Locations: 🇺🇸
Drs. Fine, Hoffman, and Packer, Eugene, Oregon, United States

Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

Phase 2

Terminated

Conditions: Inflammatory Reaction Due to Ocular Lens Prosthesis

Interventions: Drug: IBI-10090

First Posted Date: 2010-01-13

Last Posted Date: 2018-12-04

Lead Sponsor: ICON Bioscience Inc

Target Recruit Count: 6

Registration Number: NCT01048593

Locations: 🇺🇸
Altos Eye Physicians, Los Altos, California, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy